Skip to main content
PMC home page
NeuroRx logoLink to NeuroRx
. 2012 Sep 5;3(1):22–41. doi: 10.1016/j.nurx.2005.12.009

Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets

Paul J Carlson 1,2, Jaskaran B Singh 1, Carlos A Zarate 1, Wayne C Drevets 2, Husseini K Manji 1,✉
PMCID: PMC3593361  PMID: 16490411

Summary

Major depressive disorder and bipolar disorder are severe mood disorders that affect the lives and functioning of millions each year. The majority of previous neurobiological research and standard pharmacotherapy regimens have approached these illnesses as purely neurochemical disorders, with particular focus on the monoaminergic neurotransmitter systems. Not altogether surprisingly, these treatments are inadequate for many individuals afflicted with these devastating illnesses. Recent advances in functional brain imaging have identified critical neural circuits involving the amygdala and other limbic structures, prefrontal cortical regions, thalamus, and basal ganglia that modulate emotional behavior and are disturbed in primary and secondary mood disorders. Growing evidence suggests that mechanisms of neural plasticity and cellular resilience, including impairments of neurotrophic signaling cascades as well as altered glutamatergic and glucocorticoid signaling, underlie the dysregulation in these circuits. The increasing ability to monitor and modulate activity in these circuits is beginning to yield greater insight into the neurobiological basis of mood disorders. Modulation of dysregulated activity in these affective circuits via pharmacological agents that enhance neuronal resilience and plasticity, and possibly via emerging nonpharmacologic, circuitry-based modalities (for example, deep brain stimulation, magnetic stimulation, or vagus nerve stimulation) offers promising targets for novel experimental therapeutics in the treatment of mood disorders.

Key Words: Affective circuitry, bipolar disorder, brain imaging, major depressive disorder, functional imaging, therapeutics, plasticity

References

  • 1.World Health Organization. Chapter 2. Burden of Mental and Behavioral Disorders. In the WHO Report 2001: Mental Health, New Understandings, New Hope. http://www.who.int/whr/2001/en/whr01_ch2_en.pdf. 19–34, 2001.
  • 2.Fagiolini A, Kupfer DJ, Masalehdan A, Scott JA, Houck PR, Frank E. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord. 2005;7:281–285. doi: 10.1111/j.1399-5618.2005.00207.x. [DOI] [PubMed] [Google Scholar]
  • 3.Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436–1442. doi: 10.1016/S0140-6736(96)07495-8. [DOI] [PubMed] [Google Scholar]
  • 4.Revicki DA, Matza LS, Flood E, Lloyd A. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics. 2005;23:583–594. doi: 10.2165/00019053-200523060-00005. [DOI] [PubMed] [Google Scholar]
  • 5.Tohen M, Zarate ZA, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160:2099–2107. doi: 10.1176/appi.ajp.160.12.2099. [DOI] [PubMed] [Google Scholar]
  • 6.Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;160:3278–3285. doi: 10.1001/archinte.160.21.3278. [DOI] [PubMed] [Google Scholar]
  • 7.Kupfer D. The increasing medical burden in bipolar disorder. JAMA. 2005;293:2528–2530. doi: 10.1001/jama.293.20.2528. [DOI] [PubMed] [Google Scholar]
  • 8.Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med. 1996;335:1176–1181. doi: 10.1056/NEJM199610173351602. [DOI] [PubMed] [Google Scholar]
  • 9.Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–592. doi: 10.1001/archpsyc.55.7.580. [DOI] [PubMed] [Google Scholar]
  • 10.Drevets W. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol. 2001;11:240–249. doi: 10.1016/s0959-4388(00)00203-8. [DOI] [PubMed] [Google Scholar]
  • 11.Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34:13–25. doi: 10.1016/s0896-6273(02)00653-0. [DOI] [PubMed] [Google Scholar]
  • 12.Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;48:813–829. doi: 10.1016/s0006-3223(00)01020-9. [DOI] [PubMed] [Google Scholar]
  • 13.Blasi G, Bertolino A. Imaging genomics and response to treatment with antipsychotics in schizophrenia. NeuroRx. 2006;3:117–130. doi: 10.1016/j.nurx.2005.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Winokur G. The development and validity of familial subtypes in primary unipolar depression. Pharmacopsychiatry. 1982;15:142–146. doi: 10.1055/s-2007-1019527. [DOI] [PubMed] [Google Scholar]
  • 15.Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav. 2002;71:431–447. doi: 10.1016/s0091-3057(01)00687-6. [DOI] [PubMed] [Google Scholar]
  • 16.Drevets WC, Spitznagel E, Raichle ME. Functional anatomical differences between major depressive subtypes. J Cereb Blood Flow Metab. 1995;15:S93–S93. [Google Scholar]
  • 17.Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME. A functional anatomical study of unipolar depression. J Neurosci. 1992;12:3628–3641. doi: 10.1523/JNEUROSCI.12-09-03628.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wu J, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE. Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry. 1992;149:538–543. doi: 10.1176/ajp.149.4.538. [DOI] [PubMed] [Google Scholar]
  • 19.Drevets WC, Botteron K. Neuroimaging in psychiatry. In: Guze SB, editor. Adult psychiatry. St. Louis: Mosby; 1997. pp. 53–81. [Google Scholar]
  • 20.Abercrombie HC, Larson CL, Ward RT, Schaefer SM, Holden JE, Perlman SB, et al. Metabolic rate in the amygdala predicts negative affect and depression severity in depressed patients: an FDG-PET study. Neuroimage. 1996;3:S217–S217. [Google Scholar]
  • 21.Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced dperessive relapse. Arch Gen Psychiatry. 1997;54:346–374. doi: 10.1001/archpsyc.1997.01830160092012. [DOI] [PubMed] [Google Scholar]
  • 22.Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, Mathews VP, Kalnin A, Lowe MJ. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry. 2005;57:1079–1088. doi: 10.1016/j.biopsych.2005.02.021. [DOI] [PubMed] [Google Scholar]
  • 23.Haldane M, Frangou S. New insights help define the pathophysiology of bipolar affective disorder: neuroimaging and neuropathology findings. Prog Neuropsychopharm Biol Psychiatry. 2004;28:943–960. doi: 10.1016/j.pnpbp.2004.05.040. [DOI] [PubMed] [Google Scholar]
  • 24.Surguladze S, Brammer MJ, Keedwell P, Giampietro V, Young AW, Travis MJ, Williams SC, Phillips ML. A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol Psychiatry. 2005;57:201–209. doi: 10.1016/j.biopsych.2004.10.028. [DOI] [PubMed] [Google Scholar]
  • 25.Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, Weinberger DR. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry. 2005;62:146–152. doi: 10.1001/archpsyc.62.2.146. [DOI] [PubMed] [Google Scholar]
  • 26.Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, Klein S, Grusser SM, Flor H, Schumann G, Mann K, Buchel C. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci. 2005;8:20–21. doi: 10.1038/nn1366. [DOI] [PubMed] [Google Scholar]
  • 27.Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, Egan MF, Mattay VS, Hariri AR, Weinberger DR. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci. 2005;8:828–834. doi: 10.1038/nn1463. [DOI] [PubMed] [Google Scholar]
  • 28.Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW. Associative processes in addiction and reward. The role of amygdala-ventral striatum subsystems. Ann NY Acad Sci. 1999;877:412–438. doi: 10.1111/j.1749-6632.1999.tb09280.x. [DOI] [PubMed] [Google Scholar]
  • 29.Cahill L, Weinberger NM, Roozendaal B, McGaugh JL. Is the amygdala a locus of “conditioned fear”? Some questions and caveats. Neuron. 1999;23:227–228. doi: 10.1016/s0896-6273(00)80774-6. [DOI] [PubMed] [Google Scholar]
  • 30.Davis M. Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry. 1998;44:1239–1247. doi: 10.1016/s0006-3223(98)00288-1. [DOI] [PubMed] [Google Scholar]
  • 31.Ledoux J. Emotion circuits in the brain. Annu Rev Neurosci. 2000;23:155–184. doi: 10.1146/annurev.neuro.23.1.155. [DOI] [PubMed] [Google Scholar]
  • 32.Baxter LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder—a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry. 1987;44:211–218. doi: 10.1001/archpsyc.1987.01800150017003. [DOI] [PubMed] [Google Scholar]
  • 33.Biver F, Goldman S, Delvenne V, Luxen A, DeMaertelaer V, Hubain P, et al. Frontal and parietal metabolic disturbances in unipolar depression. Biol Psychiatry. 1994;36:381–388. doi: 10.1016/0006-3223(94)91213-0. [DOI] [PubMed] [Google Scholar]
  • 34.Cohen RM, Gross M, Nordahl TE, Semple WE, Oren DA, Rosenthal N. Preliminary data on the metabolic brain pattern of patients with winter seasonal affective disorder. Arch Gen Psychiatry. 1992;49:545–552. doi: 10.1001/archpsyc.1992.01820070039006. [DOI] [PubMed] [Google Scholar]
  • 35.Ebert D, Feistel H, Barocka A. Effects of sleep deprivation on the limbic system and the frontal lobes in affective disorders: a study with Tc-99m-HMPAO SPECT. Psychiatry Res. 1991;40:247–251. doi: 10.1016/0925-4927(91)90016-j. [DOI] [PubMed] [Google Scholar]
  • 36.Drevets WC, Raichle ME. Reciprocal suppression of regional cerebral blood flow during emotional versus higher cognitive processes: implications for interactions between emotion and cognition. Cogn Emotion. 1998;12:353–385. [Google Scholar]
  • 37.Brody AL, Saxena S, Silverman DHS, Alborzian S, Fairbanks LA, Phelps ME, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res Neuroimaging. 1999;91:127–139. doi: 10.1016/s0925-4927(99)00034-7. [DOI] [PubMed] [Google Scholar]
  • 38.Mayberg HS, Liotti M, Brannan SK, McGinnis BS, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156:675–682. doi: 10.1176/ajp.156.5.675. [DOI] [PubMed] [Google Scholar]
  • 39.Nobler MS, Sackeim HA, Prohovnik I, Moeller JR, Mukherjee S, Schnur DB, et al. Regional cerebral BF in mood disorders, III. Treatment and clinical response. Arch Gen Psychiatry. 1994;51:884–897. doi: 10.1001/archpsyc.1994.03950110044007. [DOI] [PubMed] [Google Scholar]
  • 40.Carmichael ST, Price JL. Limbic connections of the orbital and medial prefrontal cortex in Macaque monkeys. J Comp Neurol. 1995;363:615–641. doi: 10.1002/cne.903630408. [DOI] [PubMed] [Google Scholar]
  • 41.Mogenson GJ, Brudzynski SM, Wu M, Yang CR, Yim CCY. From motivation to action: a review of dopaminergic regulation of limbic-nucleus accumbens-ventral pallidum-pediculopontine nucleus circuitries involved in limbic-motor integration. In: Kalivas PW, Barnes CD, editors. Limbic motor circuits and neuropsychiatry. London: CRC Press; 1993. pp. 193–236. [Google Scholar]
  • 42.Price JL. Networks within the orbital and medial prefrontal cortex. Neurocase. 1999;5:231–241. [Google Scholar]
  • 43.Price JL, Carmichael ST, Drevets WC. Networks related to the orbital and medial prefrontal cortex; a substrate for emotional behavior? In: Holstege G, Bandler R, Saper CB, editors. Progress in brain research: the emotional motor system. Amsterdam: Elsevier; 1996. pp. 523–536. [DOI] [PubMed] [Google Scholar]
  • 44.Rolls E. A theory of emotion and consciousness and its application to understanding the neural basis of emotion. In: Gazzaniga MS, editor. The cognitive neurosciences. Cambridge: MIT Press; 1995. pp. 1091–1106. [Google Scholar]
  • 45.Sullivan RM, Gratton A. Lateralized effects of medial prefrontal cortex lesions on neuroendocrine and autonomic stress responses in rats. J Neurosci. 1999;19:2834–2840. doi: 10.1523/JNEUROSCI.19-07-02834.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bechara A, Dasmasio H, Tranel D, Anderson SW. Dissociation of working memory from decision-making within the human prefrontal cortex. J Neurosci. 1998;18:428–437. doi: 10.1523/JNEUROSCI.18-01-00428.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Elliott R, Dolan RJ, Frith CD. Dissociable functions in the medial and lateral orbitofrontal cortex: evidence from human neuroimaging studies. Cereb Cortex. 2000;10:308–317. doi: 10.1093/cercor/10.3.308. [DOI] [PubMed] [Google Scholar]
  • 48.Iversen SD, Mishkin M. Perseverative interference in monkeys following selective lesions of the inferior prefrontal convexity. Exp Brain Res. 1970;11:376–386. doi: 10.1007/BF00237911. [DOI] [PubMed] [Google Scholar]
  • 49.Sortres-Bayon F, Bush DE, LeDoux JE. Emotional perseveration: an update on prefrontal-amygdala interactions in fear extinction. LearnMem. 2004;11:525–535. doi: 10.1101/lm.79504. [DOI] [PubMed] [Google Scholar]
  • 50.Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, Reynolds C. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry. 1997;41:15–22. doi: 10.1016/s0006-3223(96)00097-2. [DOI] [PubMed] [Google Scholar]
  • 51.Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824–827. doi: 10.1038/386824a0. [DOI] [PubMed] [Google Scholar]
  • 52.Kegeles LS, Malone KM, Slifstein M, Anjilvel S, Xanthopoulos C, Campell M, et al. Response of cortical metabolic deficits to serotonergic challenges in mood disorders. Biol Psychiatry. 1999;45:76S–76S. doi: 10.1176/appi.ajp.160.1.76. [DOI] [PubMed] [Google Scholar]
  • 53.Hirayasu Y, Shenton ME, Salisbury DF, Kwon JS, Wible CG, Fischer LA, et al. Subgenual cingulate cortex volume in first episode psychosis. Am J Psychiatry. 1999;156:1091–1093. doi: 10.1176/ajp.156.7.1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Drevets WC, Gadde KM, Krishnan R. Neuroimaging studies of depression. In: Charney DS, Nestler EJ, Bunney BJ, editors. Neurobiology of mental illness. New York: Oxford University Press; 1999. pp. 394–418. [Google Scholar]
  • 55.Drevets WC. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res. 2000;126:413–431. doi: 10.1016/S0079-6123(00)26027-5. [DOI] [PubMed] [Google Scholar]
  • 56.Drevets WC, Videen TO, Snyder AZ, MacLeod AK, Raichle ME. Regional cerebral blood flow changes during anticipatory anxiety. Abstr Soc Neurosci. 1994;20:368–368. [Google Scholar]
  • 57.Frysztak RJ, Neafsey EJ. The effect of medial frontal cortex lesions on cardiovascular conditioned emotional responses in the rat. Brain Res. 1994;643:181–193. doi: 10.1016/0006-8993(94)90024-8. [DOI] [PubMed] [Google Scholar]
  • 58.Baxter LR, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989;46:243–250. doi: 10.1001/archpsyc.1989.01810030049007. [DOI] [PubMed] [Google Scholar]
  • 59.Drevets WC. Prefrontal cortical-amygdalar metabolism in major depression. Ann NY Acad Sci. 1999;877:614–637. doi: 10.1111/j.1749-6632.1999.tb09292.x. [DOI] [PubMed] [Google Scholar]
  • 60.Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RSJ, Dolan RJ. Depression in Parkinson’s disease: a positron emission study. Br J Psychiatry. 1994;165:333–339. doi: 10.1192/bjp.165.3.333. [DOI] [PubMed] [Google Scholar]
  • 61.Goethals I, Audenaert K, Jacobs F, Van de Wiele C, Ham H, Pyck H, Vandierendonck A, Van Heeringen C, Dierckx R. Blunted prefrontal perfusion in depressed patients performing the Tower of London task. Psychiatry Res. 2005;139:31–40. doi: 10.1016/j.pscychresns.2004.09.007. [DOI] [PubMed] [Google Scholar]
  • 62.Bench CJ, Frackowiak RS, Dolan RJ. Changes in regional cerebral blood flow on recovery from depression. Psychol Med. 1995;25:247–251. doi: 10.1017/s0033291700036151. [DOI] [PubMed] [Google Scholar]
  • 63.Apud JA. The pharmocogenomics of the dorsolateral prefrontal cortex: a new tool for the development of “target-oriented” cognitive enhancing drugs. NeuroRx. 2006;3:106–116. doi: 10.1016/j.nurx.2005.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Hooley JM, Gruber SA, Scott LA, Hiller JB, Yurgelun-Todd DA. Activation in dorsolateral prefrontal cortex in response to maternal criticism and praise in recovered depressed and healthy control participants. Biol Psychiatry. 2005;57:809–812. doi: 10.1016/j.biopsych.2005.01.012. [DOI] [PubMed] [Google Scholar]
  • 65.Carlson PJ, Thase M, Bogers W, Kupfer DJ, Drevets WC. Medial thalamic metabolism is increased in depression, and decreases with treatment. Neuroimage. 2005;26:S28–S28. [Google Scholar]
  • 66.Drevets W. PET and the functional anatomy of major depression. In: Nakajima T, Ono T, editors. Emotion, memory and behavior-study of human and nonhuman primates. Tokyo: Japan Scientific Societies Press; 1995. pp. 43–62. [Google Scholar]
  • 67.Germain A, Nofzinger EA, Kupfer DJ, Buysse DJ. Neurobiology of non-REM sleep in depression: further evidence for hypofrontality and thalamic dysregulation. Am J Psychiatry. 2004;161:1856–1863. doi: 10.1176/ajp.161.10.1856. [DOI] [PubMed] [Google Scholar]
  • 68.Keedwell PA, Andrew C, Williams SCR, Brammer MJ, Phillips ML. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry. 2005;58:843–853. doi: 10.1016/j.biopsych.2005.05.019. [DOI] [PubMed] [Google Scholar]
  • 69.Blumberg HP, Stern E, Martinez D, Ricketts S, de Asis J, White T, et al. Increased anterior cingulate and caudate activity in bipolar mania. Biol Psychiatry. 2000;48:1045–1052. doi: 10.1016/s0006-3223(00)00962-8. [DOI] [PubMed] [Google Scholar]
  • 70.Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry. 2003;160:64–75. doi: 10.1176/appi.ajp.160.1.64. [DOI] [PubMed] [Google Scholar]
  • 71.Brambilla P, Nicoletti M, Harenski K, Sassi RB, Mallinger AG, Frank E, et al. Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. Neuropsychopharmacology. 2002;27:792–799. doi: 10.1016/S0893-133X(02)00352-4. [DOI] [PubMed] [Google Scholar]
  • 72.Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, et al. Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry. 2002;51:273–279. doi: 10.1016/s0006-3223(01)01336-1. [DOI] [PubMed] [Google Scholar]
  • 73.Fossati P, Radtchenko A, Boyer P. Neuroplasticity: from MRI to depressive symptoms. Eur Neuropsychopharmacol. 2004;14:S503–S510. doi: 10.1016/j.euroneuro.2004.09.001. [DOI] [PubMed] [Google Scholar]
  • 74.Kanner A. Structural MRI changes of the brain in depression. Clin EEG Neurosci. 2004;35:46–52. doi: 10.1177/155005940403500111. [DOI] [PubMed] [Google Scholar]
  • 75.Lacerda ALT, Keshavan MS, Hardan AY, Yorbik O, Brambilla P, Sassi RB, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Soares JC. Anatomic evaluation of the orbitofrontal cortex in major depressive disorder. Biol Psychiatry. 2004;55:353–358. doi: 10.1016/j.biopsych.2003.08.021. [DOI] [PubMed] [Google Scholar]
  • 76.Dickstein DP, Milham MP, Nugent AC, Drevets WC, Charney DS, Pine DS, Leibenluft E. Frontotemporal alterations in pediatric bipolar disorder. Arch Gen Psychiatry. 2005;62:734–741. doi: 10.1001/archpsyc.62.7.734. [DOI] [PubMed] [Google Scholar]
  • 77.Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA. Amygdala and hippocampus volumes in pediatric major depression. Biol Psychiatry. 2005;57:21–26. doi: 10.1016/j.biopsych.2004.10.027. [DOI] [PubMed] [Google Scholar]
  • 78.Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry. 2001;58:545–553. doi: 10.1001/archpsyc.58.6.545. [DOI] [PubMed] [Google Scholar]
  • 79.Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorder: implications for the development of novel therapeutics. Psychopharmacol Bull. 2001;35:5–49. [PubMed] [Google Scholar]
  • 80.Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord. 2002;4:105–116. doi: 10.1034/j.1399-5618.2002.01149.x. [DOI] [PubMed] [Google Scholar]
  • 81.Coyle JT, Schwarcz R. Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry. 2000;57:90–93. doi: 10.1001/archpsyc.57.1.90. [DOI] [PubMed] [Google Scholar]
  • 82.Haydon P. GLIA: listening and talking to the synapse. Nat Rev Neurosci. 2001;2:185–193. doi: 10.1038/35058528. [DOI] [PubMed] [Google Scholar]
  • 83.Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998;95:13290–13295. doi: 10.1073/pnas.95.22.13290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry. 2000;48:756–777. doi: 10.1016/s0006-3223(00)00950-1. [DOI] [PubMed] [Google Scholar]
  • 85.Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085–1098. doi: 10.1016/s0006-3223(99)00041-4. [DOI] [PubMed] [Google Scholar]
  • 86.Ullian EM, Sapperstein SK, Christopherson KS, Barres BA. Control of synapse number by glia. Science. 2001;291:657–661. doi: 10.1126/science.291.5504.657. [DOI] [PubMed] [Google Scholar]
  • 87.Price JL. Comparative aspects of amygdala connectivity. Ann NY Acad Sci. 2003;985:50–58. doi: 10.1111/j.1749-6632.2003.tb07070.x. [DOI] [PubMed] [Google Scholar]
  • 88.Blumberg HP, Kaufman J, Martin A, Charney DS, Krystal JH, Peterson BS. Significance of adolescent neurodevelopment for the neural circuitry of bipolar disorder. Ann NY Acad Sci. 2004;1021:376–383. doi: 10.1196/annals.1308.048. [DOI] [PubMed] [Google Scholar]
  • 89.Blumberg HP, Martin A, Kaufman J, Leung HC, Skudlarski P, Lacadie CM, et al. Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from function MRI. Am J Psychiatry. 2003;160:1345–1347. doi: 10.1176/appi.ajp.160.7.1345. [DOI] [PubMed] [Google Scholar]
  • 90.Canli T, Sivers H, Thomason ME, Whitfiiled-Gabrieli S, Gabrieli JD, Gotlib IH. Brain activation to emotional words in depressed vs. healthy subjects. Neuroreport. 2004;15:2585–2588. doi: 10.1097/00001756-200412030-00005. [DOI] [PubMed] [Google Scholar]
  • 91.Chen CH, Lennox B, Jacob R, Calder A, Lupson V, Bisbrown-Chippendale R, Suckling J, Bullmore E. Explicit and implicit facial affect recognition in manic and depressed states of bipolar disorder: a functional magnetic resonance imaging study. Biol Psychiatry. 2006;59:31–39. doi: 10.1016/j.biopsych.2005.06.008. [DOI] [PubMed] [Google Scholar]
  • 92.Irwin W, Anderele MJ, Abercrombie HC, Schaefer SM, Kalin NH, Davidson RJ. Amygdalar interhemispheric functional connectivity differs between the non-depressed and depressed human brain. Neuroimage. 2004;21:674–686. doi: 10.1016/j.neuroimage.2003.09.057. [DOI] [PubMed] [Google Scholar]
  • 93.Kumari V, Mitterschiffthaler MT, Teasdale JD, Malhi GS, Brown RG, Giampietro V, Brammer MJ, Poon L, Simmons A, Williams SC, Checkley SA, Sharma T. Neural abnormalities during cognitive generation of affect in treatment-resistant depression. Biol Psychiatry. 2003;54:777–791. doi: 10.1016/s0006-3223(02)01785-7. [DOI] [PubMed] [Google Scholar]
  • 94.Lawrence NS, Williams AM, Surguladze S, Giampietro V, Brammer MJ, Andrew C, Frangou S, Ecker C, Phillips ML. Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biol Psychiatry. 2004;55:578–587. doi: 10.1016/j.biopsych.2003.11.017. [DOI] [PubMed] [Google Scholar]
  • 95.Malhi GS, Lagopoulos J, Ward PB, Kumari V, Mitchell PB, Parker GB, Ivanovski B, Sachdev P. Cognitive generation of affect in bipolar depression: an fMRI study. Eur J Neurosci. 2004;19:741–754. doi: 10.1111/j.0953-816x.2003.03159.x. [DOI] [PubMed] [Google Scholar]
  • 96.Milak MS, Parsey RV, Keilp J, Oquendo MA, Malone KM, Mann JJ. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry. 2005;62:397–408. doi: 10.1001/archpsyc.62.4.397. [DOI] [PubMed] [Google Scholar]
  • 97.Folstein SE, Peyser CE, Starkstein SE, Folstein MF. Subcortical triad of Huntington’s disease—a model for a neuropathology of depression, dementia, and dyskinesia. In: Carrol BJ, Barrett JE, editors. Psychopathology and the brain. New York: Raven Press; 1991. pp. 65–75. [Google Scholar]
  • 98.Mayeux R. Depression and dementia in Parkinson’s disease. In: Marsden CO, Fahn S, editors. Movement disorders. London: Butterworth; 1982. pp. 75–95. [Google Scholar]
  • 99.Starkstein SE, Robinson RG. Affective disorders and cerebral vascular disease. Br J Psychiatry. 1989;174:170–182. doi: 10.1192/bjp.154.2.170. [DOI] [PubMed] [Google Scholar]
  • 100.Ballantine HT, Bouckoms AJ, Thomas EK, Giriunas IE. Treatment of psychiatric illness by stereotactic cingulotomy. Biol Psychiatry. 1987;22:807–819. doi: 10.1016/0006-3223(87)90080-1. [DOI] [PubMed] [Google Scholar]
  • 101.Corsellis J, Jack AB. Neuropathological observations on yttrium implants and on undercutting in the orbito-frontal areas of the brain. In: Laitinen LV, Livingston KE, editors. Surgical approaches in psychiatry. Lancaster, England: Medical & Technical Publishing Co.; 1973. pp. 90–95. [Google Scholar]
  • 102.Knight G. Stereotactic tractotomy in the surgical treatment of mental illness. J Neurol Neurosurg Psychiatry. 1965;28:30–30. doi: 10.1136/jnnp.28.4.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Nauta WJH, Domesick V. Afferent and efferent relationships of the basal ganglia. In: Function of the basal ganglia, CIBA Foundation Symposium (Evered D, O’Connor M eds) 107: 3–29, 1984. [DOI] [PubMed]
  • 104.Newcombe R. The lesion in stereotactic subcaudate tractotomy. Br J Psychiatry. 1975;126:478–478. doi: 10.1192/bjp.126.5.478. [DOI] [PubMed] [Google Scholar]
  • 105.Nicolaidis S. Depression and neurosurgery: past, present, and future. Metab Clin Exp. 2005;54:28–32. doi: 10.1016/j.metabol.2005.01.010. [DOI] [PubMed] [Google Scholar]
  • 106.Velasco F, Velasco M, Jimenez F, Velasco AL, Salin-Pascual R. Neurobiological background for performing surgical intervention in the inferior thalamic peduncle for treatment of major depression disorders. Neurosurgery. 2005;57:439–448. doi: 10.1227/01.neu.0000172172.51818.51. [DOI] [PubMed] [Google Scholar]
  • 107.Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, Mathews VP, Kalnin A, Lowe MJ. Antidepressant effect on connectivity of the mood-regulating circuit: an fMRI study. Neuropsychopharmacology. 2005;30:1334–1344. doi: 10.1038/sj.npp.1300725. [DOI] [PubMed] [Google Scholar]
  • 108.Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J, Andrew CM, Pich EM, Williams PM, Reed LJ, Mitterschiffthaler MT, Suckling J, Bullmore ET. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry. 2004;61:877–889. doi: 10.1001/archpsyc.61.9.877. [DOI] [PubMed] [Google Scholar]
  • 109.Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, Luckenbaugh DA, Post RM. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry. 2005;57:220–228. doi: 10.1016/j.biopsych.2004.10.033. [DOI] [PubMed] [Google Scholar]
  • 110.Zarate CA, Quiroz JA, Singh JB, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54–60. doi: 10.1016/j.biopsych.2004.03.013. [DOI] [PubMed] [Google Scholar]
  • 111.Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564–566. doi: 10.1176/appi.ajp.161.3.564. [DOI] [PubMed] [Google Scholar]
  • 112.Zarate CA Jr. Cerebral metabolic changes in bipolar depressed patients treated with the D2/D3 receptor agonist pramipexole. Program of the 6th International Conference on Bipolar Disorders, Pittsburgh, PA, 2005.
  • 113.Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328:839–846. doi: 10.1056/NEJM199303253281204. [DOI] [PubMed] [Google Scholar]
  • 114.Nobler MS, Oquendo MA, Kegeles LS, et al. Decreased regional brain metabolism after ECT. Am J Psychiatry. 2001;158:305–308. doi: 10.1176/appi.ajp.158.2.305. [DOI] [PubMed] [Google Scholar]
  • 115.Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001;58:631–640. doi: 10.1001/archpsyc.58.7.631. [DOI] [PubMed] [Google Scholar]
  • 116.Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, Mayberg H. Modulation of cortical-limbic pathways in major depression. Arch Gen Psychiatry. 2004;61:34–41. doi: 10.1001/archpsyc.61.1.34. [DOI] [PubMed] [Google Scholar]
  • 117.Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology. 2003;28:1852–1865. doi: 10.1038/sj.npp.1300229. [DOI] [PubMed] [Google Scholar]
  • 118.George MS, Nahas Z, Li X, Kozel FA, Anderson B, Yamanaka K, Chae JH, Foust MJ. Novel treatment of mood disorders based on brain circuitry (ECT, MST, TMS, VNS, DBS) Semin Clin Neuropsychiatry. 2002;7:293–304. doi: 10.1053/scnp.2002.35229. [DOI] [PubMed] [Google Scholar]
  • 119.Avery DH, Holtzheimer PE, Fawaz W, Russo J, Neumaier J, Dunner DL, Haynor DR, Claypoole KH, Wajdik C, Roy-Byrne P. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry, in press. [DOI] [PubMed]
  • 120.Sapolsky R. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry. 2004;56:137–139. doi: 10.1016/j.biopsych.2004.04.012. [DOI] [PubMed] [Google Scholar]
  • 121.Chae JH, Nahas Z, Lomarev M, Denslow S, Lorberbaum JP, Bohning DE, George MS. A review of functional neuroimaging studies of vagus nerve stimulation (VNS) J Psychiatr Res. 2003;37:443–455. doi: 10.1016/s0022-3956(03)00074-8. [DOI] [PubMed] [Google Scholar]
  • 122.Narayanan JT, Watts R, Haddad N, Labar DR, Mark Li P, Filippi CG. Cerebral activation during vagus nerve stimulation: a functional MR study. Epilepsia. 2002;43:1509–1514. doi: 10.1046/j.1528-1157.2002.16102.x. [DOI] [PubMed] [Google Scholar]
  • 123.Rush A, George MS, Sackeim HA, Marangell LB, Husain M, Nahas Z, et al. Continuing benefit of VNS therapy over 2 years for treatment-resistant depression. Poster presented at the 43rd Annual NCDEU Meeting, 2003.
  • 124.Sackheim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713–728. doi: 10.1016/S0893-133X(01)00271-8. [DOI] [PubMed] [Google Scholar]
  • 125.Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58:347–354. doi: 10.1016/j.biopsych.2005.05.025. [DOI] [PubMed] [Google Scholar]
  • 126.George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58:364–373. doi: 10.1016/j.biopsych.2005.07.028. [DOI] [PubMed] [Google Scholar]
  • 127.Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355–363. doi: 10.1016/j.biopsych.2005.05.024. [DOI] [PubMed] [Google Scholar]
  • 128.Benabid A. Deep brain stimulation for Parkinson’s disease. Curr Opin Neurobiol. 2003;13:696–706. doi: 10.1016/j.conb.2003.11.001. [DOI] [PubMed] [Google Scholar]
  • 129.Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med. 1998;339:1130–1143. doi: 10.1056/NEJM199810153391607. [DOI] [PubMed] [Google Scholar]
  • 130.Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–660. doi: 10.1016/j.neuron.2005.02.014. [DOI] [PubMed] [Google Scholar]
  • 131.McIntyre CC, Savasta M, Walter BL, Vitek JL. How does deep brain stimulation work? Present understanding and future questions. J Clin Neurophysiol. 2004;21:40–50. doi: 10.1097/00004691-200401000-00006. [DOI] [PubMed] [Google Scholar]
  • 132.Jimenez F, Velasco F, Salin-Pascual R, Hernandez JA, Velasco M, Criales JL, Nicolini H. A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. Neurosurgery. 2005;57:585–593. doi: 10.1227/01.neu.0000170434.44335.19. [DOI] [PubMed] [Google Scholar]
  • 133.D’Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord. 2002;4:183–194. doi: 10.1034/j.1399-5618.2002.01203.x. [DOI] [PubMed] [Google Scholar]
  • 134.Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff KD, Gray N, Zarate CA, Charney DS. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for dificult to treat depression. Biol Psychiatry. 2003;53:707–742. doi: 10.1016/s0006-3223(03)00117-3. [DOI] [PubMed] [Google Scholar]
  • 135.Quiroz JA, Singh J, Gould TD, Denicoff KD, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry. 2004;9:756–776. doi: 10.1038/sj.mp.4001521. [DOI] [PubMed] [Google Scholar]
  • 136.Young L. Neuroprotective effects of antidepressant and mood stabilizing drugs. J Psychiatry Neurosci. 2002;27:8–9. [PMC free article] [PubMed] [Google Scholar]
  • 137.Holzheimer PE, Nemeroff CB. Advances in the treatment of depression. NeuroRx. 2006;3:42–56. doi: 10.1016/j.nurx.2005.12.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138.Brown ES, Rush AJ, McEwen BS. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology. 1999;21:474–484. doi: 10.1016/S0893-133X(99)00054-8. [DOI] [PubMed] [Google Scholar]
  • 139.McEwen B. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105–122. doi: 10.1146/annurev.neuro.22.1.105. [DOI] [PubMed] [Google Scholar]
  • 140.Sapolsky R. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925–935. doi: 10.1001/archpsyc.57.10.925. [DOI] [PubMed] [Google Scholar]
  • 141.Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis functions in patients with bipolar disorder. Br J Psychiatry. 2004;184:496–502. doi: 10.1192/bjp.184.6.496. [DOI] [PubMed] [Google Scholar]
  • 142.Brown SM, Henning S, Wellman CL. Mild, Short-term stress alters dendritic morphology in rat medial prefrontal cortex. Cereb Cortex. 2005;15:1714–1722. doi: 10.1093/cercor/bhi048. [DOI] [PubMed] [Google Scholar]
  • 143.Cook SC, Wellman CL. Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J Neurobiol. 2004;60:236–248. doi: 10.1002/neu.20025. [DOI] [PubMed] [Google Scholar]
  • 144.Wellman CL. Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J Neurobiol. 2001;49:245–253. doi: 10.1002/neu.1079. [DOI] [PubMed] [Google Scholar]
  • 145.McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol. 2004;490:13–24. doi: 10.1016/j.ejphar.2004.02.041. [DOI] [PubMed] [Google Scholar]
  • 146.Magistretti PJ, Pellerin L, Martin JL. Brain energy metabolism: an integrated cellular perspective. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. pp. 921–932. [Google Scholar]
  • 147.Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000;2:180–190. doi: 10.1034/j.1399-5618.2000.020305.x. [DOI] [PubMed] [Google Scholar]
  • 148.Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10:900–919. doi: 10.1038/sj.mp.4001711. [DOI] [PubMed] [Google Scholar]
  • 149.Kato T. Mitochondrial dysfunction in bipolar disorder: from 31P-magnetic resonance spectroscopic findings to their molecular mechanisms. Int Rev Neurobiol. 2005;63:21–40. doi: 10.1016/S0074-7742(05)63002-4. [DOI] [PubMed] [Google Scholar]
  • 150.Szabo ST, Gould TD, Manji HK. Introduction to neurotransmitters, receptors, signal transduction, and second messengers. In: Nemeroff CB, Schatzberg AF, editors. Textbook of psychopharmacology. Ed 3. Arlington, VA: The American Psychiatric Publishing; 2003. [Google Scholar]
  • 151.Bowden CL, Huang LG, Javors MA, Johnson JM, Seleshi E, McIntyre K, et al. Calcium function in affective disorders and healthy controls. Biol Psychiatry. 1988;23:367–376. doi: 10.1016/0006-3223(88)90287-9. [DOI] [PubMed] [Google Scholar]
  • 152.Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300–308. doi: 10.1001/archpsyc.61.3.300. [DOI] [PubMed] [Google Scholar]
  • 153.Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272–280. doi: 10.1016/s0959-4388(00)00208-7. [DOI] [PubMed] [Google Scholar]
  • 154.Blum R, Konnerth A. Neurotrophin-mediated rapid signaling in the central nervous system: mechanisms and functions. Physiology (Bethesda) 2005;20:70–78. doi: 10.1152/physiol.00042.2004. [DOI] [PubMed] [Google Scholar]
  • 155.Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005;6:603–614. doi: 10.1038/nrn1726. [DOI] [PubMed] [Google Scholar]
  • 156.Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257–269. doi: 10.1016/s0092-8674(03)00035-7. [DOI] [PubMed] [Google Scholar]
  • 157.Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, Graos MM, et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. 2005;12:1329–1343. doi: 10.1038/sj.cdd.4401662. [DOI] [PubMed] [Google Scholar]
  • 158.Levine ES, Crozier RA, Black IB, Plummer MR. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad Sci USA. 1998;95:10235–10239. doi: 10.1073/pnas.95.17.10235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.DeVries AC, Joh HD, Bernard O, Hattori K, Hum PD, Traystman RJ, et al. Social stress exacerbates stroke outcome by suppressing Bcl-2 expression. Proc Natl Acad Sci USA. 2001;98:11824–11828. doi: 10.1073/pnas.201215298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry. 1999;46:1181–1191. doi: 10.1016/s0006-3223(99)00177-8. [DOI] [PubMed] [Google Scholar]
  • 161.D’Sa C, Duman R. Antidepressants and neuroplasticity. Bipolar Disorder. 2002;4:183–183. doi: 10.1034/j.1399-5618.2002.01203.x. [DOI] [PubMed] [Google Scholar]
  • 162.Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S, et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci. 2000;20:4030–4036. doi: 10.1523/JNEUROSCI.20-11-04030.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163.Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry. 2001;49:753–762. doi: 10.1016/s0006-3223(00)01114-8. [DOI] [PubMed] [Google Scholar]
  • 164.Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22:3251–3261. doi: 10.1523/JNEUROSCI.22-08-03251.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 165.Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF) Pharmacol Biochem Behav. 1997;56:131–137. doi: 10.1016/S0091-3057(96)00169-4. [DOI] [PubMed] [Google Scholar]
  • 166.Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260–265. doi: 10.1016/s0006-3223(01)01083-6. [DOI] [PubMed] [Google Scholar]
  • 167.Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS. Tianeptine attenuates stress-induced morphological changes in the hippocampus. Eur J Pharmacol. 1992;222:157–162. doi: 10.1016/0014-2999(92)90830-w. [DOI] [PubMed] [Google Scholar]
  • 168.Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA. 2001;98:12796–12801. doi: 10.1073/pnas.211427898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci. 2005;25:4493–4502. doi: 10.1523/JNEUROSCI.4530-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Corson TW, Woo KK, Li PP, Warsh JJ. Cell-type specific regulation of calreticulin and Bcl-2 expression by mood stabilizer drugs. Eur Neuropsychopharmacol. 2004;14:143–150. doi: 10.1016/S0924-977X(03)00102-0. [DOI] [PubMed] [Google Scholar]
  • 171.Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol. 2004;16:83–90. doi: 10.1615/critrevneurobiol.v16.i12.90. [DOI] [PubMed] [Google Scholar]
  • 172.Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport. 1996;7:1397–1400. [PubMed] [Google Scholar]
  • 173.Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol. 1995;46:531–540. doi: 10.1016/0301-0082(95)00014-m. [DOI] [PubMed] [Google Scholar]
  • 174.Moore GJ, Bebchuck JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain gray matter. Lancet. 2000;356:1241–1242. doi: 10.1016/s0140-6736(00)02793-8. [DOI] [PubMed] [Google Scholar]
  • 175.Moore GJ, CB, Glitz DA, et al. Lithium increases gray matter in the prefrontal and subgenual prefrontal cortices in treatment responsive bipolar disorder patients. Submitted. [DOI] [PubMed]
  • 176.Cirelli C, Tononi G. Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J Neurosci. 2000;20:9187–9194. doi: 10.1523/JNEUROSCI.20-24-09187.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177.Payne JL, Quiroz JA, Zarate CA, Manji HK. Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry. 2002;52:921–926. doi: 10.1016/s0006-3223(02)01676-1. [DOI] [PubMed] [Google Scholar]
  • 178.Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA. 1996;93:8455–8459. doi: 10.1073/pnas.93.16.8455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 179.Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells. Curr Biol. 1996;6:1664–1668. doi: 10.1016/s0960-9822(02)70790-2. [DOI] [PubMed] [Google Scholar]
  • 180.Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 2005;30:1223–1237. doi: 10.1038/sj.npp.1300731. [DOI] [PubMed] [Google Scholar]
  • 181.Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci. 2003;116:1175–1186. doi: 10.1242/jcs.00384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182.Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry. 2004;9:734–755. doi: 10.1038/sj.mp.4001518. [DOI] [PubMed] [Google Scholar]
  • 183.Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3α regulates production of Alzheimer’s disease amyloid-β peptides. Nature. 2003;423:435–439. doi: 10.1038/nature01640. [DOI] [PubMed] [Google Scholar]
  • 184.Gould TD, Manji HK. The wnt signaling pathway in bipolar disorder. Neuroscientist. 2002;8:497–511. doi: 10.1177/107385802237176. [DOI] [PubMed] [Google Scholar]
  • 185.Jope RS, Bijur GN. Mood stabilizers, glycogen synthase kinase-3 β and cell survival. Mol Psychiatry. 2002;7:S35–S45. doi: 10.1038/sj.mp.4001017. [DOI] [PubMed] [Google Scholar]
  • 186.Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun. 2005;329:177–181. doi: 10.1016/j.bbrc.2005.01.117. [DOI] [PubMed] [Google Scholar]
  • 187.Smith E, Frenkel B. Glucocorticoid s inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3β-dependent and -independent manner. J Biol Chem. 2005;280:2388–2394. doi: 10.1074/jbc.M406294200. [DOI] [PubMed] [Google Scholar]
  • 188.Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev. 2002;22:373–384. doi: 10.1002/med.10011. [DOI] [PubMed] [Google Scholar]
  • 189.Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev. 2002;22:373–384. doi: 10.1002/med.10011. [DOI] [PubMed] [Google Scholar]
  • 190.Endres M, Meisel A, Biniszkiewicz D, et al. DNA methyltransferase contributes to delayed ischemic brain injury. J Neurosci. 2000;20:3175–3181. doi: 10.1523/JNEUROSCI.20-09-03175.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 191.Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. Neurochem. 2004;89:1358–1367. doi: 10.1111/j.1471-4159.2004.02406.x. [DOI] [PubMed] [Google Scholar]
  • 192.Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal F. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Nanomolecular Med. 2004;5:235–241. doi: 10.1385/NMM:5:3:235. [DOI] [PubMed] [Google Scholar]
  • 193.Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J Neurosci. 2003;23:9418–9427. doi: 10.1523/JNEUROSCI.23-28-09418.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 194.Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci USA. 2003;100:2041–2046. doi: 10.1073/pnas.0437870100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 195.Weaver I, Cervoni N, Champagne F, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847–854. doi: 10.1038/nn1276. [DOI] [PubMed] [Google Scholar]
  • 196.Tremolizzo L, Doueiri MS, Dong E, et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry. 2005;57:500–509. doi: 10.1016/j.biopsych.2004.11.046. [DOI] [PubMed] [Google Scholar]
  • 197.Manji HK, Lenox RH. Ziskin-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry. 1999;46:1328–1351. doi: 10.1016/s0006-3223(99)00235-8. [DOI] [PubMed] [Google Scholar]
  • 198.Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, Bloom AK, Davis DJ, Gobeske KT, Sweatt JD, Manji HK, Arnsten AFT. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science. 2004;306:882–884. doi: 10.1126/science.1100021. [DOI] [PubMed] [Google Scholar]
  • 199.Einat H, MH. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Submitted. [DOI] [PubMed]
  • 200.Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry. 2000;57:95–97. doi: 10.1001/archpsyc.57.1.95. [DOI] [PubMed] [Google Scholar]
  • 201.Haggerty JJ, Prange AJ. Borderline hypothyroidism and depression. Annu Rev Med. 1995;46:37–46. doi: 10.1146/annurev.med.46.1.37. [DOI] [PubMed] [Google Scholar]
  • 202.Bauer M, London ED, Silverman DH, Rasgon N, Kirchheiner J, Whybrow PC. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry. 2003;36(Suppl 3):S215–S221. doi: 10.1055/s-2003-45133. [DOI] [PubMed] [Google Scholar]
  • 203.Cole DP, Thase ME, Mallinger AG, Soares JC, Luther JF, Kupfer DJ, Frank E. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002;159:116–121. doi: 10.1176/appi.ajp.159.1.116. [DOI] [PubMed] [Google Scholar]
  • 204.Frye MA, Denicoff KD, Bryan AL, Smith-Jackson EE, Ali SO, Luckenbaugh D, Leverich GS, Post RM. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry. 1999;156:1909–1914. doi: 10.1176/ajp.156.12.1909. [DOI] [PubMed] [Google Scholar]
  • 205.Joffe R. Refractory depression: treatment strategies, with particular reference to the thyroid axis. J Psychiatry Neurosci. 1997;22:327–331. [PMC free article] [PubMed] [Google Scholar]
  • 206.Prange A. Novel uses of thyroid hormones in patients with affective disorders. Thyroid. 1996;6:537–543. doi: 10.1089/thy.1996.6.537. [DOI] [PubMed] [Google Scholar]
  • 207.Ruel J, Faure R, Dussault JH. Regional distribution of nuclear T3 receptors in rat brain and evidence for preferential localization in neurons. J Endocrinol Invest. 1985;8:343–348. doi: 10.1007/BF03348511. [DOI] [PubMed] [Google Scholar]
  • 208.Schwartz HL, Oppenheimer JH. Nuclear triiodothyronine receptor sites in brain: probable identity with hepatic receptors and regional distribution. Endocrinol. 1978;103:267–273. doi: 10.1210/endo-103-1-267. [DOI] [PubMed] [Google Scholar]
  • 209.Marangell LB, Ketter TA, George MS, Pazzaglia PJ, Callahan AM, Parekh P, Andreason PJ, Horwitz B, Herscovitch P, Post RM. Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Am J Psychiatry. 1997;154:224–230. doi: 10.1176/ajp.154.2.224. [DOI] [PubMed] [Google Scholar]
  • 210.Bauer M, London ED, Rasgon N, Berman SM, Frye MA, Altshuler LL, Mandelkern MA, Bramen J, Voytek B, Woods R, Mazziotta JC, Whybrow PC. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry. 2005;10:456–469. doi: 10.1038/sj.mp.4001647. [DOI] [PubMed] [Google Scholar]
  • 211.Ketter TA, Wang PW. The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. J Clin Psychiatry. 2003;64(Suppl 3):15–20. [PubMed] [Google Scholar]
  • 212.Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull. 2002;36:35–83. [PubMed] [Google Scholar]
  • 213.Stahl SM. Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx. 2006;3:3–9. doi: 10.1016/j.nurx.2005.12.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 214.Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79–88. doi: 10.4088/jcp.v60n0203. [DOI] [PubMed] [Google Scholar]
  • 215.Calabresi P, Siniscalchi A, Pisani A, Stefani A, Mercuri NB, Bernardi G. A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Neurology. 1996;47:557–562. doi: 10.1212/wnl.47.2.557. [DOI] [PubMed] [Google Scholar]
  • 216.Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia. 1986;27:490–497. doi: 10.1111/j.1528-1157.1986.tb03573.x. [DOI] [PubMed] [Google Scholar]
  • 217.Wang SJ, Huange CC, Hsu KS, Tsai JJ, Gean PW. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Synapse. 1996;24:248–255. doi: 10.1002/(SICI)1098-2396(199611)24:3<248::AID-SYN7>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  • 218.Zarate CA, Payne J, Quiroz JA, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161:171–174. doi: 10.1176/appi.ajp.161.1.171. [DOI] [PubMed] [Google Scholar]
  • 219.Zarate CA, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57:430–432. doi: 10.1016/j.biopsych.2004.11.023. [DOI] [PubMed] [Google Scholar]
  • 220.Cameron HA, McEwen BS, Gould E. Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. J Neurosci. 1995;15:4687–4692. doi: 10.1523/JNEUROSCI.15-06-04687.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 221.Zarate CA, Singh JB, Quiroz J, et al. A double-blind placebo controlled study of memantine in major depression. Am J Psychiatry. 2006;163:153–155. doi: 10.1176/appi.ajp.163.1.153. [DOI] [PubMed] [Google Scholar]
  • 222.Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354. doi: 10.1016/s0006-3223(99)00230-9. [DOI] [PubMed] [Google Scholar]
  • 223.Zarate CA Jr, Singh JB, Carlson PJ, Brutsche N, Ameli R, Luckenbaugh DA, et al. Robust, rapid, and relatively sustained anti-depressant effects with a single dose of an NMDA antagonist in treatment resistant major depression: a double-blind placebo-controlled study. Arch Gen Psychiatry, in press.
  • 224.Bleakman D, Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology. 1998;37:1187–1204. doi: 10.1016/s0028-3908(98)00139-7. [DOI] [PubMed] [Google Scholar]
  • 225.Borges K, Dingledine R. AMPA receptors: molecular and functional diversity. Prog Brain Res. 1998;116:153–170. doi: 10.1016/s0079-6123(08)60436-7. [DOI] [PubMed] [Google Scholar]
  • 226.Black M. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacol (Berl) 2005;179:154–163. doi: 10.1007/s00213-004-2065-6. [DOI] [PubMed] [Google Scholar]
  • 227.Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098) Neuropharmacology. 2001;40:1028–1033. doi: 10.1016/s0028-3908(00)00194-5. [DOI] [PubMed] [Google Scholar]
  • 228.Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology. 2003;44:1013–1021. doi: 10.1016/s0028-3908(03)00104-7. [DOI] [PubMed] [Google Scholar]
  • 229.Lauterborn J, Lynch G, Vanderklish P, Arai A, et al. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000;20:8–21. doi: 10.1523/JNEUROSCI.20-01-00008.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 230.Lauterborn J, Truong GS, Baudry M, Bi X, Lynch G, Gall C. Chronic elevation of brain-derived neurotrophic factor by AM-PAkines. J Pharmacol Exp Ther. 2003;307:297–305. doi: 10.1124/jpet.103.053694. [DOI] [PubMed] [Google Scholar]
  • 231.Knapp RJ, Goldengerg R, Shuck C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol. 2002;440:27–35. doi: 10.1016/s0014-2999(02)01338-9. [DOI] [PubMed] [Google Scholar]
  • 232.Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trend Neurosci. 1996;19:267–271. doi: 10.1016/S0166-2236(96)20019-0. [DOI] [PubMed] [Google Scholar]
  • 233.Maiese K, Vincent A, Lin SH, Shaw T. Group I and group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res. 2000;62:257–272. doi: 10.1002/1097-4547(20001015)62:2<257::AID-JNR10>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 234.Palucha A, Tatarczynska E, Branski P, et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology. 2004;46:151–159. doi: 10.1016/j.neuropharm.2003.09.006. [DOI] [PubMed] [Google Scholar]
  • 235.Schoepp D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther. 2001;299:12–20. [PubMed] [Google Scholar]
  • 236.Chojnacka-Wojcik E, Klodzinska A, Pilc A. Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs. 2001;2:1112–1119. [PubMed] [Google Scholar]
  • 237.Spooren WP, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther. 2000;295:1267–1275. [PubMed] [Google Scholar]
  • 238.Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective, and systemically active mGlu5 receptor antagonist. Br J Pharmacol 1423–1430, 2001. [DOI] [PMC free article] [PubMed]
  • 239.Tatarczynska E, Klodzinska A, Kroczka B, Chojnacka-Wojcik E, Pilc A. The antianxiety-like effects of antagonists of grouop I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacol (Berl) 2001;158:94–99. doi: 10.1007/s002130100798. [DOI] [PubMed] [Google Scholar]
  • 240.Drevets WC, Raichle ME. Neuroanatomical circuits in depression: implications for treatment mechanisms. Psychopharmacol Bull. 1992;28:261–274. [PubMed] [Google Scholar]
  • 241.Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. European Neuropsychopharmacology. 2002;12:527–544. doi: 10.1016/s0924-977x(02)00102-5. [DOI] [PubMed] [Google Scholar]
  • 242.Drevets WC, Thase M, Price JC, Bogers W, Greer PJ, Kupfer DK. Antidepressant drug effects on regional glucose metabolism in major depression. Soc Neurosci Abstr. 2002;32:803.3–803.3. [Google Scholar]
  • 243.Holthoff VA, Beuthien-Baumann B, Zundorf G, Triemer A, Ludecke S, Winiecki P, Koch R, et al. Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatr Scand. 2004;110:184–194. doi: 10.1111/j.1600-0447.2004.00351.x. [DOI] [PubMed] [Google Scholar]
  • 244.Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158:899–905. doi: 10.1176/appi.ajp.158.6.899. [DOI] [PubMed] [Google Scholar]
  • 245.Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000;48:830–843. doi: 10.1016/s0006-3223(00)01036-2. [DOI] [PubMed] [Google Scholar]
  • 246.Nobler MS, Roose SP, Prohovnik I, Moeller JR, Louie J, Van Heertum RL, Sackheim HA. Regional cerebral blood flow in mood disorders, V. Effects of antidepressant medication in late-life depression. Am J Geriatr Psychiatry. 2000;8:289–296. [PubMed] [Google Scholar]
  • 247.Nofzinger EA, Berman S, Fasiczka A, Miewald JM, Meltzer CC, Price JC, Sembrat RC, et al. Effects of bupropion SR on anterior paralimbic function during waking and REM sleep in depression: preliminary findings using [18F]-FDG PET. Psychiatry Res: Neuroimaging Section. 2001;106:95–111. doi: 10.1016/s0925-4927(01)00067-1. [DOI] [PubMed] [Google Scholar]
  • 248.Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry. 2002;59:250–261. doi: 10.1001/archpsyc.59.3.250. [DOI] [PubMed] [Google Scholar]
  • 249.Smith GS, Reynolds CF, Pollock B, Derbyshire S, Nofzinger E, Dew MA, Houck PR, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatry. 1999;156:683–689. doi: 10.1176/ajp.156.5.683. [DOI] [PubMed] [Google Scholar]

Articles from NeuroRx are provided here courtesy of Am. Soc. for Experimental NeuroTherapeutics

RESOURCES